Literature DB >> 24363506

How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Enzo Ierardi1, Floriana Giorgio1, Giuseppe Losurdo1, Alfredo Di Leo1, Mariabeatrice Principi1.   

Abstract

Therapeutic management of Helicobacter pylori (H. pylori) remains an unsolved issue. Indeed, no therapeutic regimen is able to cure the infection in all treated patients, and in many the infection persists despite the administration of several consecutive standard therapies. Although antibiotic resistance reports describe alarming results, the outcome of therapeutic regimens does not seem to parallel this scenario in most cases, since a successful performance is often reached in more than 80% of cases. However, the phenomenon of increasing antibiotic resistance is being closely studied, and the results show controversial aspects even in the same geographic area. For the continents of Europe, America, Asia, Africa, and Oceania, minimal and maximal values of resistance to the main antibiotics (clarithromycin, amoxicillin, metronidazole, and levofloxacin) feature wide ranges in different countries. The real enigma is therefore linked to the several different therapeutic regimens, which show results that often do not parallel the in vitro findings even in the same areas. A first aspect to be emphasized is that some regimens are limited by their use in very small geographic districts. Moreover, not all therapeutic trials have considered bacterial and host factors affecting the therapeutic outcome. The additional use of probiotics may help to reduce adverse events, but their therapeutic impact is doubtful. In conclusion, the "ideal therapy", paradoxically, appears to be a "utopia", despite the unprecedented volume of studies in the field and the real breakthrough in medical practice made by the discovery and treatment of H. pylori. The ample discrepancies observed in the different areas do not encourage the development of therapeutic guidelines that could be valid worldwide. On these bases, one of the main challenges for the future might be identifying a successful solution to overcome antibiotic resistances. In this context, geography must be considered a relevant matter.
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Geography; Helicobacter pylori; Therapeutic outcome; Therapeutic regimens

Mesh:

Substances:

Year:  2013        PMID: 24363506      PMCID: PMC3857438          DOI: 10.3748/wjg.v19.i45.8168

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  168 in total

1.  Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years.

Authors:  Seiichi Kato; Shigeru Fujimura
Journal:  Pediatr Int       Date:  2009-06-26       Impact factor: 1.524

2.  Prevalence and determinants of Helicobacter pylori sero-positivity in the Australian adult community.

Authors:  Nirmala Pandeya; David C Whiteman
Journal:  J Gastroenterol Hepatol       Date:  2011-08       Impact factor: 4.029

3.  Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status.

Authors:  H K Parsons; M J Carter; D S Sanders; T Winstanley; A J Lobo
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

4.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: result of the HPFEZ randomised study.

Authors:  Mounia Lahbabi; Samia Alaoui; Karima El Rhazi; Mohammed El Abkari; Chakib Nejjari; Afaf Amarti; Bahia Bennani; Mustapha Mahmoud; Adil Ibrahimi; Dafr Allah Benajah
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-11-16       Impact factor: 2.947

Review 5.  Is the molecular basis of metronidazole resistance in microaerophilic organisms understood?

Authors:  George L Mendz; Francis Mégraud
Journal:  Trends Microbiol       Date:  2002-08       Impact factor: 17.079

6.  Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000.

Authors:  Kathlen Wolle; Andreas Leodolter; Peter Malfertheiner; Wolfgang König
Journal:  J Med Microbiol       Date:  2002-08       Impact factor: 2.472

7.  Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents.

Authors:  Lyudmila Boyanova; Ivan Mitov
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

8.  Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.

Authors:  Juan Qian; Feng Ye; Jun Zhang; Yan-Mei Yang; Hui-Ming Tu; Qi Jiang; Li Shang; Xiao-Lin Pan; Rui-Hua Shi; Guo-Xin Zhang
Journal:  Helicobacter       Date:  2012-08-21       Impact factor: 5.753

9.  16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marcel R de Zoete; Niek L A Arents; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods.

Authors:  Lyudmila Boyanova; Galina Gergova; Rossen Nikolov; Lubomir Davidkov; Victor Kamburov; Christo Jelev; Ivan Mitov
Journal:  Diagn Microbiol Infect Dis       Date:  2008-01-14       Impact factor: 2.803

View more
  44 in total

Review 1.  Flagellin glycosylation with pseudaminic acid in Campylobacter and Helicobacter: prospects for development of novel therapeutics.

Authors:  Abu Iftiaf Md Salah Ud-Din; Anna Roujeinikova
Journal:  Cell Mol Life Sci       Date:  2017-10-27       Impact factor: 9.261

2.  Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic.

Authors:  Muhammad Miftahussurur; Modesto Cruz; Phawinee Subsomwong; José A Jiménez Abreu; Celso Hosking; Hiroyuki Nagashima; Junko Akada; Yoshio Yamaoka
Journal:  Am J Trop Med Hyg       Date:  2017-02-13       Impact factor: 2.345

3.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: how should rifabutin be managed in rescue regimens?

Authors:  Giuseppe Losurdo; Andrea Iannone; Floriana Giorgio; Mariabeatrice Principi; Alfredo Di Leo; Enzo Ierardi
Journal:  United European Gastroenterol J       Date:  2015-12-15       Impact factor: 4.623

4.  Reply to letter to the editor: "The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world".

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  United European Gastroenterol J       Date:  2016-05-27       Impact factor: 4.623

Review 5.  Use of probiotics in the fight against Helicobacter pylori.

Authors:  Paolo Ruggiero
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

6.  The diagnosis and management of H. pylori infection in Singapore.

Authors:  Claire Alexandra Zhen Chew; Tong Fong Lye; Daphne Ang; Tiing Leong Ang
Journal:  Singapore Med J       Date:  2017-05       Impact factor: 1.858

Review 7.  Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.

Authors:  Sinéad M Smith; Colm O'Morain; Deirdre McNamara
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 8.  Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment.

Authors:  Traci L Testerman; James Morris
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

9.  Use of selected lactic acid bacteria in the eradication of Helicobacter pylori infection.

Authors:  Jin-Eung Kim; Min-Soo Kim; Yeo-Sang Yoon; Myung-Jun Chung; Do-Young Yum
Journal:  J Microbiol       Date:  2014-10-03       Impact factor: 3.422

10.  Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype.

Authors:  Li-Juan Zhao; Yan-Qiang Huang; Bing-Pu Chen; Xiao-Qiang Mo; Zan-Song Huang; Xiao-Feng Huang; Lian-Deng Wei; Hong-Yu Wei; Yuan-Hong Chen; Hua-Ying Tang; Gan-Rong Huang; Yan-Chun Qin; Xiao-Hua Li; Lu-Yao Wang
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.